CD38 expression in paediatric leukaemia and lymphoma: implications for antibody targeted therapy

Br J Haematol. 2018 Jan;180(2):292-296. doi: 10.1111/bjh.14310. Epub 2016 Sep 8.

Authors

Anne E Bras¹, Auke Beishuizen², Anton W Langerak¹, Mojca Jongen-Lavrencic³, Jeroen G Te Marvelde¹, Marry M van den Heuvel-Eibrink², C Michel Zwaan², Jacques J M van Dongen¹, Vincent H J van der Velden¹

Affiliations

¹ Laboratory Medical Immunology, Department of Immunology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands.
² Department of Paediatric Oncology/Haematology, Erasmus MC - Sophia Children's Hospital, University Medical Centre Rotterdam, Rotterdam, The Netherlands.
³ Department of Haematology, Erasmus MC, University Medical Centre Rotterdam, Rotterdam, The Netherlands.

PMID: 27604396
DOI: 10.1111/bjh.14310

No abstract available

Keywords: CD38; immunophenotyping; leukaemia; lymphoma; paediatric.

Publication types

Letter

MeSH terms

ADP-ribosyl Cyclase 1 / antagonists & inhibitors
ADP-ribosyl Cyclase 1 / genetics
ADP-ribosyl Cyclase 1 / metabolism*
Adolescent
Age Factors
Antineoplastic Agents, Immunological / therapeutic use
Biomarkers, Tumor
Child
Child, Preschool
Gene Expression
Humans
Infant
Leukemia / drug therapy
Leukemia / genetics
Leukemia / metabolism*
Lymphoma / drug therapy
Lymphoma / genetics
Lymphoma / metabolism*
Molecular Targeted Therapy

Substances

Antineoplastic Agents, Immunological
Biomarkers, Tumor
ADP-ribosyl Cyclase 1